Zura Bio Limited (NASDAQ:ZURA) Given Average Rating of “Moderate Buy” by Brokerages

Zura Bio Limited (NASDAQ:ZURA) has received an average rating of “Moderate Buy” from the six brokerages that are currently covering the stock, Marketbeat.com reports. One research analyst has rated the stock with a sell recommendation, one has given a hold recommendation, three have issued a buy recommendation and one has assigned a strong buy recommendation to the company. The average 1 year target price among analysts that have issued ratings on the stock in the last year is $10.75.

ZURA has been the subject of a number of recent analyst reports. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Zura Bio in a report on Tuesday, October 14th. Leerink Partnrs upgraded Zura Bio to a “strong-buy” rating in a research note on Sunday, November 23rd. Wall Street Zen cut Zura Bio from a “hold” rating to a “sell” rating in a research note on Sunday, November 16th. HC Wainwright cut their target price on Zura Bio from $3.00 to $2.00 and set a “neutral” rating on the stock in a research report on Tuesday, August 19th. Finally, Chardan Capital reiterated a “buy” rating and set a $10.00 target price on shares of Zura Bio in a research note on Friday, November 14th.

Zura Bio Stock Performance

ZURA stock opened at $4.12 on Wednesday. The firm has a market cap of $267.88 million, a P/E ratio of -6.34 and a beta of 0.24. Zura Bio has a 1 year low of $0.97 and a 1 year high of $4.68. The stock has a 50-day simple moving average of $3.80 and a 200-day simple moving average of $2.49.

Zura Bio (NASDAQ:ZURA) last released its quarterly earnings results on Thursday, November 13th. The company reported ($0.21) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.19) by ($0.02). On average, equities research analysts predict that Zura Bio will post -0.65 EPS for the current year.

Institutional Investors Weigh In On Zura Bio

A number of institutional investors have recently made changes to their positions in the company. Bank of America Corp DE boosted its holdings in Zura Bio by 31.9% in the fourth quarter. Bank of America Corp DE now owns 41,222 shares of the company’s stock worth $103,000 after purchasing an additional 9,966 shares during the period. Scientech Research LLC acquired a new stake in shares of Zura Bio during the third quarter worth $45,000. Savant Capital LLC lifted its position in shares of Zura Bio by 190.4% in the 2nd quarter. Savant Capital LLC now owns 32,409 shares of the company’s stock worth $34,000 after buying an additional 21,249 shares during the last quarter. Forefront Wealth Partners LLC acquired a new position in shares of Zura Bio in the 3rd quarter valued at about $93,000. Finally, Armistice Capital LLC grew its position in shares of Zura Bio by 1.6% during the 3rd quarter. Armistice Capital LLC now owns 1,560,000 shares of the company’s stock valued at $6,755,000 after buying an additional 24,000 shares during the last quarter. 61.14% of the stock is currently owned by institutional investors.

About Zura Bio

Zura Bio Limited, a clinical-stage biotechnology company, focuses on developing novel medicines for immune and inflammatory disorders. It develops Tibulizumab, an IgG-scFv bispecific dual-antagonist antibody engineered by the fusion of ixekizumab and tabalumab that neutralizes IL-17A and BAFF, which is in Phase 2 clinical trial development; ZB-168, a monoclonal antibody that binds and neutralizes the IL-7 receptor chain that impact on diseases driven by IL7 and thymic stromal lymphopoietin immune pathways; and Torudokimab, a monoclonal antibody that neutralizes IL33, which is in Phase 2 clinical trial development.